NFκB drives TERT promoter reactivation in cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

1. Beyond Telomeres: Unveiling the Extratelomeric Functions of TERT in B-Cell Malignancies.Cancers · 2025
   Review
2. Norrin in cancer: from a promising prognostic biomarker to a novel therapeutic target.Frontiers in oncology · 2025
   Review
3. Short-Term TERT Inhibition Impairs Cellular Proliferation via a Telomere Length-Independent Mechanism and Can Be Exploited as a Potential Anticancer Approach.Cancers · 2023
   Article
4. Emerging mechanisms of telomerase reactivation in cancer.Trends in cancer · 2022
   Review
5. p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy.Journal for immunotherapy of cancer · 2020
   Article
6. Diverse regulatory manners of human telomerase reverse transcriptase.Cell communication and signaling : CCS · 2019
   Review
7. Evidence for the Involvement of the Master Transcription Factor NF-κB in Cancer Initiation and Progression.Biomedicines · 2018
   Review
8. Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, andOncotarget · 2017
   Article
9. Transcriptional Regulation of Telomerase Reverse Transcriptase (TERT) by MYC.Frontiers in cell and developmental biology · 2017
   Review
10. Telomerase reactivation in cancers: Mechanisms that govern transcriptional activation of the wild-type vs. mutant TERT promoters.Transcription · 2016
    Review

Corrections and comments

• Comment on
  Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.2015

Authors and funding

1 author at 1 institution in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as